This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Manitoba directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
Combination therapy enhances the antiviral activity of IFN-λ against SARS-CoV-2 and MERS-CoV.
Virus research · 2025
Latest funding
- $20,000
38th Annual Canadian Society of Immunology (CSI) 2026 meeting
CIHR · 2025 · Principal investigator
- $967,725
Role of type III interferons in regulating mucosal immunity in a healthy gut versus ulcerative colitis
CIHR · 2024 · Nominated PI
- $1,139,850
Role of mucosal neutrophils in driving HIV/HPV infection and disease progression
CIHR · 2024 · Co-investigator
1 publications.
Combination therapy enhances the antiviral activity of IFN-λ against SARS-CoV-2 and MERS-CoV.
Zadeh VR, Lew JM, Zahoor MA, Santer D, Feld JJ, Falzarano D
38th Annual Canadian Society of Immunology (CSI) 2026 meeting
Principal investigators: Murooka, Thomas T; Arsenio, Janilyn; Banerji, Versha; Ghia, Jean-Eric; Santer, Deanna; Su, Ruey-Chyi; Tremblay, Cedric S
Keywords: Autoimmune-Related Diseases; Cancer Immunology; Host-Pathogen Interactions; Immunology; Infectious Disease; Vaccines And Immunotherapies
Role of type III interferons in regulating mucosal immunity in a healthy gut versus ulcerative colitis
Principal investigators: Santer, Deanna
Keywords: Gut Barrier; Immune Regulation; Inflammation; Interferons; Lymphocytes; Mucosal Immunity; Ulcerative Colitis
Role of mucosal neutrophils in driving HIV/HPV infection and disease progression
Principal investigators: Murooka, Thomas T
Keywords: Bacterial Vaginosis; Hiv-1; Inflammation; Microscopy; Mouse Models Of Infection; Neutrophils; Papillmovirus; T Cells; Vaginal Mucosa
Evaluation of IFN-lambda as a novel antiviral therapeutic for genital HPV and HSV-2 infection in vivo
Principal investigators: Murooka, Thomas T; Ashkar, Ali A; Santer, Deanna
Keywords: Female Genital Tract; Herpes Simplex Virus (Hsv); Human Papillomavirus (Hpv); Immune Activation; Inflammation; Innate Immunity; Interferon-Lambda; Mouse Models Of Infection; Vaginal Epithelial Barrier; Virus Replication
Understanding type III interferon receptor regulation as a novel therapeutic target for ulcerative colitis
Principal investigators: Olumade, Testimony
Keywords: Cell Biology; Colitis; Immunology; Interferons; Microbiome; Signaling
Engineering a new interferon lambda therapy for gastrointestinal diseases
Principal investigators: Santer, Deanna
Keywords: Interferons; gastrointestinal; protein engineering; lipid nanoparticle; self-amplifying RNA; gene therapy; immune regulation; inflammation
Defining the cellular and molecular mechanisms regulating type III interferon responses
Principal investigators: Santer, Deanna
Defining the cellular and molecular mechanisms regulating type III interferon responses
Principal investigators: Santer, Deanna
Peginterferon lambda to treat outpatients with COVID-19 to prevent severe disease: Focus on variants of concern
Principal investigators: Feld, Jordan J
Keywords: Covid-19; Host Antiviral Response; Pan-Variant; Pegylated Interferon Lambda; Prevention Of Hospitalization And Mortality; Randomized Controlled Trial; Reduction In Viral Load; Simplified Outpatient Treatment; Transmission Prevention; Variants Of Concern
Characterization of interferon-lambda 1 as a treatment for COVID-19
Principal investigators: Tyrrell, D. Lorne J; Feld, Jordan J
Keywords: Covid-19; Human Immune Cells; Inflammation; Interferon-Lambda; Sars-Cov-2
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.